• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Core Facilities

Tissue Microarray and Imaging (Pathology)



Hofer MD, Bismar TA, Kuefer R, et al. Determining Pathologic Risk Factors for Disease Progression in High Risk Prostate Cancer Patients Treated with Radical Prostatectomy. Submitted 2004.

Rubin MA, Bismar TA, Andrén O, et al. Decreased AMACR Expression in Localized Prostate Cancer is Associated with Biochemical Recurrence and Cancer Specific Death. Submitted.

Varambally S, Yu J, Laxman B, et al. Integrative Proteomic and Genomic Analysis of Prostate Cancer Progression. Submitted.

Bismar TA, Perner S, Febbo PG, Hofer MD, Chinnaiyan AM, Rubin MA. Foamy Gland Prostate Carcinoma: Is Gleason Grading Valid In Areas Of Foamy Gland Tumors? Modern pathology 2004;17(1)A593.

Browne TJ, Hirsch MS, Brodsky G, Welch WR, Loda MF, Rubin MA. Prospective evaluation of AMACR (P504S) and basal cell markers in the assessment of routine prostate needle biopsy specimens. Hum Pathol 2004;35(12):1462-8.

Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004;6(5):503-12.

Hofer MD, Kuefer R, Varambally S, et al. The role of metastasis-associated protein 1 in prostate cancer progression. Cancer Res 2004;64(3):825-9.

Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004;64(11):3814-22.

Rubin MA, Zerkowski MP, Camp RL, et al. Quantitative Determination of Expression of the Prostate Cancer Protein alpha-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA): A Novel Paradigm for Automated and Continuous Biomarker Measurements. Am J Pathol 2004;164(3):831-40.

Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004;64(19):6854-7.

Garraway LA, Widlund HR, Rubin MA, et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Submitted.

Bismar, Demichelis, Riva, et al. Defining Aggressive Prostate Cancer Using a 12 Gene Model. Submitted.